Varieties of repetitive behavior in autism: comparisons to mental retardation.
J W Bodfish, F J Symons, D E Parker...
https://pubmed.ncbi.nlm.nih.gov/11055459/Actively Recruiting
Led by Virginia Commonwealth University · Updated on 2026-08-11
200
Participants Needed
4
Research Sites
N/A
Total Duration
This research aims to better understand congenital myotonic dystrophy CDM and childhood myotonic dystrophy ChDM, which are inherited disorders affecting multiple body systems in children. CDM appears at birth with serious symptoms like breathing problems and feeding difficulties, while ChDM begins after birth but before age 10 with similar but generally less severe effects. The study seeks to develop better clinical assessments and biomarkers for these conditions to aid future drug trials, especially since current adult trials cannot be directly applied to children due to differences in symptoms and disease progression. The study will enroll up to 200 children with either CDM or ChDM. No treatments are given as part of this study participants will continue to receive their usual medical care. Study visits will take place at the start of the study Baseline, and then again at 12 months and 24 months. During these visits, researchers will perform various physical and cognitive tests to track changes in mobility, muscle strength, language, sleepiness, behavior, and quality of life. Participants will be involved in detailed assessments including walking tests, motor function evaluations, hand strength measurements, and questionnaires on sleepiness and quality of life. Researchers will also monitor language abilities, repetitive behaviors, and adaptive skills. These evaluations will help measure changes over 24 months and improve the tools used in clinical trials for these diseases. The study is sponsored by Virginia Commonwealth University and is expected to continue through June 2030.
CONDITIONS
Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension
R
Ruby Langeslay, MPH
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Virginia Commonwealth University
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - At enrollment
Participants visit the study site to complete initial physical and cognitive tests to assess mobility, muscle strength, language, behavior, and quality of life.
1 visit (in-person)
Duration - 12 months after baseline
Participants return for a follow-up visit to repeat the assessments and track changes since baseline.
1 visit (in-person)
Duration - 24 months after baseline
Participants complete the final visit to assess changes in physical and cognitive function over 24 months.
1 visit (in-person)
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
J W Bodfish, F J Symons, D E Parker...
https://pubmed.ncbi.nlm.nih.gov/11055459/Craig Campbell, Rebecca Sherlock, Pierre Jacob...
https://pubmed.ncbi.nlm.nih.gov/15060232/Robert J Osborne, Xiaoyan Lin, Stephen Welle...
https://pubmed.ncbi.nlm.nih.gov/19223393/Stacey D Wagner, Adam J Struck, Riti Gupta...
https://pubmed.ncbi.nlm.nih.gov/27681373/Thurman M Wheeler
https://pubmed.ncbi.nlm.nih.gov/19019311/Craig M McDonald, Jessica R Marden, Perry B Shieh...
https://pubmed.ncbi.nlm.nih.gov/36749302/Kiera N Berggren, Man Hung, Melissa M Dixon...
https://pubmed.ncbi.nlm.nih.gov/29901230/Nicholas E Johnson, Elizabeth Luebbe, Eileen Eastwood...
https://pubmed.ncbi.nlm.nih.gov/23611887/Britt-Marie Eriksson, Anne-Berit Ekström, Marie Peny-Dahlstrand
https://pubmed.ncbi.nlm.nih.gov/31701525/Y H Fu, A Pizzuti, R G Fenwick...
https://pubmed.ncbi.nlm.nih.gov/1546326/Virginia Commonwealth University
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Collaborating Sponsor